Focus on the Multimodal Role of Biomarkers in Breast Cancer

Author(s): Damanpreet K. Lang, Ankita Sood, Rajwinder Kaur*, Rashmi Arora, Tapan Behl*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 35 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Breast cancer is the most common type of malignancy affecting women worldwide and also stands being the most diagnosed one. Mammography is considered as the golden standard for diagnosis but there are high chances that it can give false- negative as well as false-positive test results. Finding cost-effective, readily available diagnosis along with increased sensitivity as well as specificity is the need right now to decrease the mortality as well as the morbidity rate. The application of biomarkers to clinical use has paved the way for a better prognosis, diagnosis, detection, screening and better clinical results. The efficacy of the treatment is enhanced. Biomarkers are known to cause an advancement in breast cancer study and are expected to improve the quality of life in patients. Not only tissue biomarkers but serum and circulating biomarkers are also of significance in patients. This review highlights the particulars about the current use and application of biomarkers in an effective prognosis, detection, treatment of the breast cancer and also the ones which are currently being studied under clinical trials and have the potential to be advantageous and more specific in the future.

Keywords: Breast cancer, biomarkers, diagnosis, global, cytotoxic, screening.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 35
Year: 2021
Published on: 11 January, 2021
Page: [3686 - 3701]
Pages: 16
DOI: 10.2174/1381612827999210111185213
Price: $65

Article Metrics

PDF: 189